Wednesday November 3, 12:03 pm Eastern Time
Company Press Release
SOURCE: Wall Street Transcript
The Wall Street Transcript Publishes Biotechnology Management Performance Review
NEW YORK, Nov. 3 /PRNewswire/ -- Six leading analysts and sixteen Biotechnology CEOs examine the Biotechnology sector in the latest issue of The Wall Street Transcript (212/952-7433) or twst.com
In a vital review of this sector for investors and industry professionals, this significant 112-page report features an extensive overview of Biotech management performance:
1) The TWST confidential Off The Record survey of management performance at 15 Biotechnology firms asked market insiders about the ability of management teams to create shareholder value. In a sector where many management teams are criticized for failing to deliver on the hype, some CEOs receive top marks for their efforts.
James Vincent, Chairman & CEO of Biogen (Nasdaq: BGEN - news), has a solid team behind him, according to a money manager. ``Biogen's stock is obviously down today, but, quite frankly, the management team there is very effective as a team. They deserve credit, as does Jim Vincent for hiring the right people and for having a good, solid team.'
For a free excerpt from the interview of Prudential Securities Managing Director Peter Drake that lists reasons why he sees tremendous upside for Biogen see archive.twst.com
Sean Lance, Chairman, President & CEO of Chiron (Nasdaq: CHIR - news), is hailed as a seasoned executive by one Wall Streeter. ``Sean Lance at Chiron has brought some financial discipline and a strong operational and strategic vision to the company, helping redirect their resources to the most rewarding of opportunities. So Sean Lance gets a big A plus in my book.'
For a list of articles on Chiron see twst.com
Triple A rating for Imclone Systems (Nasdaq: IMCL - news), headed by Samuel Waksal, President & CEO, and Carl S. Goldfischer, CFO, in the opinion of one Wall Streeter. ``Sam Waksal is a guy who, roughly two years ago, had this new program called C225, a monoclonal antibody to the EGF for sector and consumer sales. He had all kinds of controversies surrounding him and the company. Waksal has managed to transform that, with a tremendous contribution on the part of his CFO, Carl Goldfischer. Together, they've brought credibility and clinical validation to the company, to the stock.'
For a list of articles on Imclone see twst.com
Edward Fritzky, Chairman & CEO of Immunex Corp. (Nasdaq: IMNX - news), is singled out by a buy sider. ``The CEO at Immunex, Ed Fritzky, has done a great job as far as shareholder value, managing financials, and maintaining morale at a company that was really in the midst of a turnaround.'
For a list of articles on Immunex see twst.com Additional management teams reviewed in Off The Record include:
Alkermes, Amgen, Cephalon, Creative Biomolecules, CV Therapeutics, Genetech, Genzyme, Gilead Sciences, Medimmune, Myriad Genetics, PE Biosystems and Transkaryotic Therapies.
Read Off The Record and learn who industry insiders think is ``just excellent' and which firm has a management team ``that needs to go away.'
To read an excerpt of the Off The Record review of Amgen's Gordon Binder see archive.twst.com
This survey is a uniquely valuable resource for checking the ``Street's' view of senior management.
The Biotech Management Review includes:
2) Sixteen extensive (average 2,500 words) CEO Interviews with top management from the following sector firms discussing their future plans and outlook for their firm and the Biotechnology sector:
Abgenix, Alta Genetics, BioTime, Commonwealth Biotechnologies, Corvas International, Genzyme Transgenics, Interleukin Genetics, LifeCell Corp., North American Scientific, Novagen Ltd., Targeted Genetics, Texas Biotechnology, Renal Care Group and Xenometrix.
James Vincent, Chairman and CEO of Biogen offers this statement for investors, ``The first thing I usually ask them is, 'Are you a Biogen stock holder?' If they say no, I ask them next if they have something against making money because if you look at our 10-year track record we have out performed the S&P 500 in a very strong period for the S&P by approximately a factor of two on a compounded basis.'
Stanley Crooke, M.D., Ph.D., Chairman and CEO of Isis Pharmaceuticals (Nasdaq: ISIP - news) explains about their drug ISIS-2302 which is currently in development to treat Crohn's disease, `` We have recently completed enrollment of the pivotal quality trial. We anticipate that assuming that the data from this trial is as positive as the Phase II data that we would initiate the necessary regulatory filings and plan on filing an NDA probably in the first quarter of next year. This would represent our second NDA for an antisense drug and one that has a very substantial commercial opportunity.'
Pauline Gee, President of Xenometrix (OTC Bulletin Board: XENO - news), looks forward, stating ``While we can be optimistic about some measure of success independently, we cannot fully realize this technology on our own. We need a partner in a technology alliance that would help us, provide us with really good quality data so that we can model the data to be predictive using this technology in the clinic. So that if you or I were going to use a drug, that the whole industry will be able to predict and minimize the side effects of that drug to you or I.'
This valuable 112-page Biotech issue includes:
3) An in-depth roundtable forum on the Biotechnology Industry (13,700+ words), four leading analysts: Margaret Malloy of Hambrecht & Quist, Jay Silverman of Robertson Stephens, William Slattery of Amerindo Investment Advisors and Elise Wang of PaineWebber examine the unprecedented amount of biotech M&A activity, reimbursement issues, clinical trial safety concerns, novel therapies, cancer treatments, genomics and drug development, blockbuster and overhyped drugs, second generation drugs, valuation factors, late-stage product plays, emerging companies that are discovery stage plays and advice for sector investors, including top stock recommendations.
For more details see twst.com
4) Outlook for Biotechnology -- Extensive Analyst Interview (4,900 words), Peter Drake, Ph.D., Managing Director of Equity Research with Prudential Securities examines investing in later-stage vs. development-stage companies, M&A outlook, management performance and specific stock recommendations.
5) Biotechnology Stocks - Detailed Analyst Interview (4,200 words), Kurt von Emster, Vice-President and Portfolio Manager with Franklin Advisers investigates faster FDA approvals, joint ventures, new products, discovery-stage and genomics companies and shares his biotechnology stock recommendations.
For more details see twst.com
To obtain a copy of this insightful 112-page report, see twst.com or call (212) 952-7433. This special section is also included in the Healthcare Sector of TWST Online at twst.com
The Wall Street Transcript is a premier weekly investment publication interviewing market professionals for serious investors for over 35 years. Available at twst.com TWST Online provides free Interview excerpts. For highlights, recent recommendations by analysts and money managers and biotech news, visit twst.com
The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations |
